GSK Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 5.1% compared to GSK PLC's net margin of 21.81%. GSK PLC's return on equity of 19.22% beat BioNTech SE's return on equity of -3.39%.

GSK PLC has a consensus price target of $41.72, signalling upside risk potential of 12.66%. On the other hand BioNTech SE has an analysts' consensus of $142.37 which suggests that it could grow by 23.98%. Given that BioNTech SE has higher upside potential than GSK PLC, analysts believe BioNTech SE is more attractive than GSK PLC.

GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.943%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.2%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are larger than BioNTech SE quarterly revenues of $1.3B. GSK PLC's net income of $530.1M is higher than BioNTech SE's net income of $276.6M. Notably, GSK PLC's price-to-earnings ratio is 23.39x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.91x versus 9.27x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 5.1% compared to GSK PLC's net margin of 23.56%. GSK PLC's return on equity of 19.22% beat Gilead Sciences's return on equity of 2.5%.

GSK PLC has a consensus price target of $41.72, signalling upside risk potential of 12.66%. On the other hand Gilead Sciences has an analysts' consensus of $113.60 which suggests that it could grow by 6.79%. Given that GSK PLC has higher upside potential than Gilead Sciences, analysts believe GSK PLC is more attractive than Gilead Sciences.

GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.2%. Gilead Sciences offers a yield of 2.91% to investors and pays a quarterly dividend of $0.79 per share. GSK PLC pays 94.91% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

GSK PLC quarterly revenues are $10.4B, which are larger than Gilead Sciences quarterly revenues of $7.6B. GSK PLC's net income of $530.1M is lower than Gilead Sciences's net income of $1.8B. Notably, GSK PLC's price-to-earnings ratio is 23.39x while Gilead Sciences's PE ratio is 287.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.91x versus 4.65x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 5.1% compared to GSK PLC's net margin of -117.16%. GSK PLC's return on equity of 19.22% beat Moderna's return on equity of -29.09%.

GSK PLC has a consensus price target of $41.72, signalling upside risk potential of 12.66%. On the other hand Moderna has an analysts' consensus of $50.22 which suggests that it could grow by 89.23%. Given that Moderna has higher upside potential than GSK PLC, analysts believe Moderna is more attractive than GSK PLC.

GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.2%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are larger than Moderna quarterly revenues of $956M. GSK PLC's net income of $530.1M is higher than Moderna's net income of -$1.1B. Notably, GSK PLC's price-to-earnings ratio is 23.39x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.91x versus 3.22x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 5.1% compared to GSK PLC's net margin of -91.76%. GSK PLC's return on equity of 19.22% beat Novavax's return on equity of --.

GSK PLC has a consensus price target of $41.72, signalling upside risk potential of 12.66%. On the other hand Novavax has an analysts' consensus of $15.17 which suggests that it could grow by 103.03%. Given that Novavax has higher upside potential than GSK PLC, analysts believe Novavax is more attractive than GSK PLC.

GSK PLC has a beta of 0.579, which suggesting that the stock is 42.135% less volatile than S&P 500. In comparison Novavax has a beta of 3.148, suggesting its more volatile than the S&P 500 by 214.784%.

GSK PLC has a quarterly dividend of $0.40 per share corresponding to a yield of 4.2%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 94.91% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GSK PLC quarterly revenues are $10.4B, which are larger than Novavax quarterly revenues of $88.3M. GSK PLC's net income of $530.1M is higher than Novavax's net income of -$81M. Notably, GSK PLC's price-to-earnings ratio is 23.39x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.91x versus 1.71x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.